Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clemens-Martin Wendtner

Showing results (31-40 of 106) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|December 16, 2010
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsMichaela Patz, Polina Isaeva, Nche Forcob, et al.
Blood|August 19, 2008
Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive diseaseChristian Philipp Pallasch, Alexandra Schulz, Nadine Kutsch, et al.
Experimental Hematology|February 20, 2003
High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectorsClemens-Martin Wendtner, Christian Kurzeder, Hans D Theiss, et al.
Experimental Hematology|December 10, 2003
Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotidesHans D Theiss, David M Kofler, Hildegard Büning, et al.
Frontiers in Immunology|July 12, 2021
EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected PatientsThomas Luft, Clemens-Martin Wendtner, Florentina Kosely, et al.
Leukemia & Lymphoma|November 24, 2015
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBruce D Cheson, Wolfram Brugger, Gandhi Damaj, et al.
Future Oncology (London, England)|July 11, 2015
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progressionPetra Langerbeins, Jasmin Bahlo, Christina Rhein, et al.
Infection|July 11, 2022
Clinical and virological features of first human monkeypox cases in GermanySebastian Noe, Sabine Zange, Michael Seilmaier, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panelBruce D Cheson, Clemens-Martin Wendtner, Angelika Pieper, et al.
International Journal of Cancer|July 30, 2010
Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locusLukas P Frenzel, Rainer Claus, Nadine Plume, et al.
Pageof 11

Showing results (31-40 of 106) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|December 16, 2010
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsMichaela Patz, Polina Isaeva, Nche Forcob, et al.
Blood|August 19, 2008
Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive diseaseChristian Philipp Pallasch, Alexandra Schulz, Nadine Kutsch, et al.
Experimental Hematology|February 20, 2003
High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectorsClemens-Martin Wendtner, Christian Kurzeder, Hans D Theiss, et al.
Experimental Hematology|December 10, 2003
Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotidesHans D Theiss, David M Kofler, Hildegard Büning, et al.
Frontiers in Immunology|July 12, 2021
EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected PatientsThomas Luft, Clemens-Martin Wendtner, Florentina Kosely, et al.
Leukemia & Lymphoma|November 24, 2015
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBruce D Cheson, Wolfram Brugger, Gandhi Damaj, et al.
Future Oncology (London, England)|July 11, 2015
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progressionPetra Langerbeins, Jasmin Bahlo, Christina Rhein, et al.
Infection|July 11, 2022
Clinical and virological features of first human monkeypox cases in GermanySebastian Noe, Sabine Zange, Michael Seilmaier, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panelBruce D Cheson, Clemens-Martin Wendtner, Angelika Pieper, et al.
International Journal of Cancer|July 30, 2010
Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locusLukas P Frenzel, Rainer Claus, Nadine Plume, et al.
Pageof 11